Castle Biosciences Inc. (NASDAQ: CSTL) stock closed at 19.46 per share at the end of the most recent trading day (a -1.87% change compared to the prior day closing price) with a volume of 274.62K shares and market capitalization of 523.67M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 135 people. Castle Biosciences Inc. CEO is Derek J. Maetzold.

The one-year performance of Castle Biosciences Inc. stock is -16.72%, while year-to-date (YTD) performance is -17.33%. CSTL stock has a five-year performance of %. Its 52-week range is between 9.2601 and 29.59, which gives CSTL stock a 52-week price range ratio of 50.17%

Castle Biosciences Inc. currently has a PE ratio of -11.10, a price-to-book (PB) ratio of 1.46, a price-to-sale (PS) ratio of 6.24, a price to cashflow ratio of 230.60, a PEG ratio of -, a ROA of -11.88%, a ROC of -12.79% and a ROE of -12.87%. The company’s profit margin is -47.13%, its EBITDA margin is -43.90%, and its revenue ttm is $98.70 Million , which makes it $3.75 revenue per share.

Of the last four earnings reports from Castle Biosciences Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.92 for the next earnings report. Castle Biosciences Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Castle Biosciences Inc. is Strong Buy (1), with a target price of $47.4, which is +143.58% compared to the current price. The earnings rating for Castle Biosciences Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Castle Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Castle Biosciences Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 15.41, ATR14 : 0.82, CCI20 : 39.08, Chaikin Money Flow : 0.10, MACD : 0.98, Money Flow Index : 44.90, ROC : -0.92, RSI : 61.18, STOCH (14,3) : 41.01, STOCH RSI : 0.00, UO : 52.72, Williams %R : -58.99), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Castle Biosciences Inc. in the last 12-months were: Bradbury Daniel (Sold 16 460 shares of value $329 857 ), Cole G. Bradley (Option Excercise at a value of $0), Daniel M. Bradbury (Sold 49 974 shares of value $1 151 998 ), Derek J. Maetzold (Option Excercise at a value of $0), Derek J. Maetzold (Sold 36 600 shares of value $852 883 ), Frank Stokes (Option Excercise at a value of $13 520), Goldberg Ellen (Buy at a value of $138 008), Goldberg Ellen (Option Excercise at a value of $0), Harrison Miles (Option Excercise at a value of $0), Juvenal Tobin (Sold 0 shares of value $-14 753 ), Kim Caple (Option Excercise at a value of $0), Kristen Oelschlager (Option Excercise at a value of $17 155), Maetzold Derek (Sold 64 151 shares of value $1 457 820 ), Olson Tiffany (Option Excercise at a value of $0), Tobin W. Juvenal (Option Excercise at a value of $0)